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Abstract
The protein kinase pUL97 of human cytomegalovirus plays important but incompletely defined roles in viral replication. Concerning the
early phase of infection, it is postulated that pUL97 possesses regulatory functions in gene expression and/or DNA synthesis. Here we report
that pUL97 interacts with an essential component of the replication complex, the DNA polymerase processivity factor pUL44. Interaction
was determined by yeast two-hybrid and coimmunoprecipitation analyses and was mapped to the pUL97 region 366–459. In vitro kinase
assays demonstrated that pUL44, coimmunoprecipitated either from transfected or from infected cells, is phosphorylated by pUL97 (but not
by a catalytically inactive pUL97-mutant). In infected fibroblasts, immunofluorescence analysis revealed that pUL97 and pUL44 accumulate
in the nucleus and are both incorporated into viral replication centers. The treatment with inhibitors of DNA synthesis or pUL97 kinase
activity largely prevented colocalization. Thus, pUL97 may be indirectly involved in viral genome replication by modifying the replication
cofactor pUL44.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human cytomegalovirus (HCMV) infections are a major
cause of morbidity and mortality among immunocompro-
mised persons, especially transplant recipients and patients
with AIDS. Severe clinical problems also frequently arise
from the infection of the fetus. Antiviral agents currently
licensed for the treatment of HCMV infection include in-
hibitors of viral DNA synthesis, such as ganciclovir (GCV),
foscarnet (FOS), cidofovir (CDV), and the prodrugs valgan-
ciclovir and valacyclovir (reviewed by Curran and Noble,
2001; Lowance et al., 1999). GCV and related nucleoside
analogues are converted by the viral kinase pUL97 into the
active monophosphorylated metabolites. This phosphoryla-
tion step is therefore confined to virus-infected cells, a
prerequisite explaining the specific antiviral action of these
compounds. Importantly, it was shown that pUL97, al-
though phosphorylating nucleoside analogues, is not a nat-
ural nucleoside kinase (Michel et al., 1996) and might
therefore not directly, but possibly indirectly, be involved in
the replication processes connected with DNA synthesis.
pUL97 belongs to a group of homologous protein kinase C
(PKC)-like herpesviral kinases with serine/threonine specific-
ity. Several studies have shown that pUL97 is particularly
important for efficient replication (Michel et al., 1996; Prichard
et al., 1999; Wolf et al., 2001; Krosky et al., 2003). Deletion
of the UL97 gene in the viral genome was found to be
critical for the infection of cultured cells, resulting in a
drastic decline in virus replication. As far as the specific
function of pUL97 within the viral replication cycle is
concerned, it seems suggestive that pUL97 is involved in
the activation of phosphorylation-dependent viral regulatory
proteins. However, only a limited amount of data has been
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published concerning the identification of phosphorylated
target proteins.
The presented study provides evidence that the protein
kinase pUL97 physically interacts with a component of the
viral replication complex, the early phosphoprotein pUL44
which is known to stimulate the activity of the HCMV DNA
polymerase (Anders and McCue, 1996). We could demon-
strate that pUL44 is phosphorylated by pUL97 in vitro and
that both proteins colocalize within replication centers in the
nuclei of infected cells. These findings might indicate the
importance of pUL44–pUL97 interaction for early replica-
tion steps.
Results
pUL97 physically interacts with pUL44 in the yeast two-
hybrid assay
Although the expression and activity of the HCMV pro-
tein kinase pUL97 have been investigated in detail, the
identification of phosphorylated target proteins is still a
matter of controversial discussion. Recently, however, the
UL44 protein was proposed as a putative natural substrate
of the viral kinase, possibly referring to the role of pUL97
in the early phase of infection. In a congress report by
Krosky et al., the in vitro phosphorylation of purified re-
combinant pUL44 by pUL97 was demonstrated (24th Inter-
national Herpesvirus Workshop, Boston, 1999; P. Krosky,
personal communication). Therefore, we performed a yeast
two-hybrid analysis to address the question of interaction
between the two viral proteins. pUL44 (in fusion to activa-
tion domain GAL4AD) was coexpressed with pUL97 (in
fusion to DNA binding domain GAL4BD) (Fig. 1a, top).
When assayed for -Gal activity by filter lift tests, a specific
subset of clones stained dark blue, indicative of interaction.
Furthermore, a catalytically inactive point mutant of pUL97
(K355M) was likewise positive, indicating that the kinase
activity, in particular autophosphorylation of pUL97, was
not required for interaction. Then, the specificity of protein
interaction was further analyzed by testing a series of
HCMV-encoded as well as heterologous viral proteins for
interaction with pUL97 (Fig. 1a, middle and bottom). An-
other component of the HCMV replication complex, the
single-stranded DNA-binding protein pUL57, clearly
stained negative in coexpression with pUL97, tested in
fusion to both GAL4AD and GAL4BD. Furthermore,
pUL57 did not interact with pUL44 in the yeast two-hybrid
system (data not shown). Other HCMV proteins, such as
pUL84, IE2p86, pUL69, pp65, pp150, pUL26, and pUL97
itself, as well as heterologous viral proteins, such as EBNA1
and SV40-T, were also negative for interaction with pUL97.
With respect to the findings described for Fig. 3 concerning
intracellular localization, it should be mentioned that sev-
eral of these proteins were found to be associated with
subnuclear compartments, such as viral replication centers
or ND10 domains, e.g., pUL44 (Sarisky and Hayward,
1996; Yamamoto et al., 1998), pUL57 (Ahn et al., 1999),
pUL84 (Xu et al., 2002), and IE2p86 (Ahn and Hayward,
1997; Hofmann et al., 2002). This might be highly relevant
for the localization of pUL97 itself (see below). Combined,
these findings show that among a series of viral proteins
tested for interaction with pUL97, only pUL44 resulted in
positive signals, strongly suggesting the specificity of inter-
action.
In a second approach, we generated a series of deletion
mutants of pUL97 to map the region which is responsible
for interaction with pUL44 (Fig. 1b). As determined by two
independent methods (filter lift and ONPG assays), -ga-
lactosidase (-Gal) positive clones were obtained for all
mutants containing the central portion of pUL97, whereas
those mutants lacking the central region were negative.
C-terminal deletion of pUL97 up to position 459 did not
prevent interaction and also N-terminal deletion up to po-
sition 366 was tolerable. The results obtained by filter lift
staining were supported by those obtained by the ONPG
assay. In conclusion, the interaction with pUL44 is medi-
ated by the central region of pUL97 spanning amino acids
366 to 459. It is noteworthy that this region is distinct from
other protein interaction domains of pUL97. We recently
identified two cellular interactors of pUL97 and these two
proteins contact the regions adjacent to the pUL44 interac-
tion domain (M. Marschall, unpublished data).
pUL44 is coimmunoprecipitated with pUL97 from infected
or transfected cells
Given the information from the yeast two-hybrid system,
we first investigated whether interaction between pUL97
and pUL44 was detectable in HCMV-infected human fibro-
blasts. Infection was performed at high as well as at low
m.o.i., and mock-infected cells served as a negative control.
Lysates from these samples were used for immunoprecipi-
tation with a monoclonal antibody against pUL44 (Fig. 2a).
When analyzed by Western blotting, specific coimmunopre-
cipitation of pUL97 was detected in samples from high
m.o.i., but no signals were obtained in samples from mock-
infection or low m.o.i. With respect to the lack of signals
under low m.o.i., it should be taken into consideration that
production of both proteins was quantitatively limited (see
infection control). In addition, all samples used for immu-
noprecipitation with a nonspecific control antibody were
also negative for pUL97. Thus, pUL97, at least in part, is
complexed with pUL44 in HCMV-infected fibroblasts.
In addition to that, an experiment was performed to
exclude the possibility of an indirect interaction mediated
by other viral proteins. For this, we overexpressed pUL97
and pUL44 in 293T cells as fusion proteins with C-terminal
HA or FLAG tags, respectively. When putative complexes
were immunoprecipitated by MAb-HA and subsequently
analyzed on a Western blot by the use of MAb-FLAG, we
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detected interaction between pUL97 and pUL44 (but not
pUL84, which was chosen as a specificity negative control).
Thus, although we cannot exclude the possibility of an
indirect interaction through a cellular bridging protein, it is
unequivocal that the pUL97–pUL44 interaction occurs in
the absence of other viral proteins.
Colocalization of pUL97 with pUL44 in nuclear
replication centers
Infected fibroblasts were analyzed by immunofluores-
cence double staining to visualize viral protein complexes
on the single-cell level (Fig. 3a). In a kinetic study, covering
Fig. 1. Interaction between pUL97 and pUL44 in the yeast two-hybrid system. (a) Yeast strain Y153 was transformed with constructs pAS-UL97 and
pACT-UL44, or empty vectors as a control. The catalytically inactive mutant K355M of pUL97 was compared to wild-type and the specificity of interaction
was illustrated by the use of a series of expression constructs for other viral proteins (expressed in fusion to either GAL4BD or GAL4AD, as indicated). The
constructs expressing simian virus 40 large T antigen (SV40-T) or tumor suppressor protein (p53) were used as a positive control for interaction. Staining
of clones by the filter lift assay (-Gal activity) is shown and the results were reproduced by at least two independent experiments (, -Gal positive; ,
-Gal negative). (b) The interaction region within pUL97 was mapped by the use of C-terminal and N-terminal deletion mutants. pUL44 was coexpressed
in its wild-type form. Signals of interaction were determined by two independent methods, the filter lift and the ONPG assay. -Gal positive clones are
pictured as blue colonies and quantified by relative ONPG values (1.00 means full reactivity between pUL44 and pUL97 wild-type).
Fig. 2. Interaction between pUL97 and pUL44 in the coimmunoprecipitation assay. (a) HFFs were infected with HCMV strain AD169 at m.o.i.s 1, 0.1, or
mock-infected. Cell lysates were prepared at 3 days postinfection. The success of infection was monitored by the analysis of small aliquots on Western blots
using HCMV- specific monoclonal antibodies as indicated (infection control). Lysates were used for immunoprecipitation with monoclonal antibodies
reactive for pUL44 (MAb-UL44) or nonreactive for pUL44 (MAb-FLAG as a negative control). The coimmunoprecipitation of pUL97 was detected on
Western blots by the use of MAb-UL97 (with specific bands marked by arrowheads). The strong background staining in the lower part of the blot is due to
a reactivity of the secondary antibody (HRP-coupled anti-mouse) against the heavy chain of the precipitation antibodies (mouse MAbs, Ig-HC). Marker bands:
205, 116, 97.4, 68, 45, 29 kDa. (b) 293T cells were cotransfected with the indicated combinations of constructs expressing tagged versions of pUL97, pUL44,
or pUL84, and GFP served as a control. Specific precipitation of pUL97 was achieved by the use of MAb-HA and the coprecipitated pUL44 was detected
on a Western blot using MAb-FLAG. Expression of all proteins was controlled either by fluorescence microscopy (GFP) or Western blot analysis of lysate
controls taken prior to coimmunoprecipitation (MAb-HA and MAb-FLAG, not shown).
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immediate early (12 h), early (24–48 h), and late (72 h)
phases of HCMV infection, the intensifying colocalization
of pUL97 with pUL44 was demonstrated. At time points
earlier than 24 h, only slight staining in diffuse localizations
was obtained for both proteins (data not shown). In the early
phase, from 24 to 48 h, pUL44 accumulated in intranuclear
granules. Subsequently, this staining pattern steadily con-
verted into the fine-structured and defined viral replication
centers (Ahn et al., 1999; Giesen et al., 2000). As an addi-
tional marker for the formation of replication centers
(Yamamoto et al., 1998; Ahn et al., 1999), a costaining
between the viral DNA-associated accessory protein
pUL112–113 and pUL44 was performed (data not shown).
pUL97, on the other hand, initially occurred in a homoge-
neous nuclear distribution which, to an increasing degree,
altered toward a distinct colocalization with pUL44. It
seemed that pUL44 preceded the localization in replication
centers, while pUL97 only partly colocalized with these
subnuclear structures early during infection. At 72 h, how-
ever, this picture completely changed in a way that pUL97
accumulated within replication centers and showed a strong
colocalization with pUL44 (Fig. 3a, panels i–m, at higher
magnification, n–q). This finding is consistent with the data
obtained by coimmunoprecipitation at 72 h postinfection
(see Figs. 2a and 4g–i).
In addition, an experiment was performed with a virus
variant that carries a point mutation in pUL97 (M460I). This
mutation confers viral GCV resistance and lowers, but does
not completely prevent, pUL97 protein kinase activity
(Marschall et al., 2001). In this case again, a distinct pattern
of colocalization between pUL97(M460I) and pUL44 in
replication centers was obtained. Therefore, we conclude
that, starting with the early phase of HCMV infection,
pUL97 wild-type as well as a GCV-resistant mutant, asso-
ciates with pUL44 within viral nuclear compartments.
We further addressed the question of whether the protein
kinase activity of pUL97 was functionally connected with
this interaction (Fig. 3b). For this, we analyzed the effect of
inhibitors of viral DNA synthesis (CDV) and pUL97 kinase
activity (NGIC-I and Go¨6976) on the formation of replica-
tion centers. CDV, a therapeutically important nucleotide
analogue blocking viral DNA synthesis, prevented the for-
mation of replication centers and the distinct colocalization
between pUL97 and pUL44. Importantly, a similar effect
was noted for NGIC-I and Go¨6976 (indolocarbazoles),
which were recently described as potent anticytomegalovi-
ral compounds effecting a drastic reduction of the in vitro
replication efficiency at the stage of pUL97 (Marschall et
Fig. 3. Colocalization of pUL97 and pUL44 in nuclear replication centers.
(a) HFFs were infected with HCMV strain AD169 at an m.o.i. of 0.1 and
harvested at the time points indicated. Fixed cells were double-stained for
the production of viral proteins using antibodies against pUL97 (rabbit
anti-UL97) and pUL44 (mouse MAb-UL44) in a combined incubation.
Secondary antibodies were used for staining pUL97 in green (anti-rabbit-
FITC) and pUL44 in red (anti-mouse-Cy3). Colocalization was visualized
by a merge of the two microscopic determinations. Counterstaining of the
cell nuclei was achieved by the use of DAPI. Arrows indicate the appear-
ance of viral replication centers (magnification, 400). Panels n to q show
an enlarged image of one infected nucleus at 72 h (magnification, 630).
Panels r to u show a virus mutant, carrying a GCV resistance-conferring
point mutation in UL97 (M460I). (b) HFFs were infected with HCMV
strain AD169 at an m.o.i. of 0.1 and various inhibitors were added to the
culture medium after incubation with the inoculum virus at the concentra-
tions indicated (CDV, inhibitor of viral DNA synthesis; NGIC-I and
Go¨6976, protein kinase inhibitors targeting pUL97; Go¨7874 and AG490,
non-pUL97-specific protein kinase inhibitors). Infected cells were har-
vested at 4 days postinfection and used for double-staining as described
above.
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al., 2001, 2002; Zimmermann et al., 2000). In comparison,
two other protein kinase inhibitors (Go¨7874 and AG490),
lacking specificity for pUL97, did not show an effect on the
pUL97–pUL44 colocalization pattern. Thus, the finding
suggests that these inhibitors of the pUL97 kinase activity
prevent the formation of replication centers.
pUL97 phosphorylates pUL44 after precipitation from
transfected or infected cells
The interaction and colocalization of pUL97 with pUL44
raised the question of whether pUL44 was phosphorylated
by pUL97 during this process. We performed transfection
experiments and immunoprecipitation of the produced pro-
teins to analyze the precipitates in an in vitro kinase assay
(Fig. 4a–f). By doing so, it became evident that pUL44 is
already phosphorylated to a limited degree when precipi-
tated alone in the absence of pUL97. This might be due to
a yet unknown cellular protein kinase, exerting this activity
after unwarranted coprecipitation from the cell lysates. In
the presence of pUL97, however, phosphorylation of
pUL44 was strongly increased and was detected in the form
of a phosphorylated pUL44 double-band (Fig. 4a). In addi-
tion, the double-band specific for pUL97 autophosphoryla-
tion (see also Marschall et al., 2002) proved the desired
activity of the viral kinase in these samples. Expression
controls were obtained by assaying aliquots of the cell
lysates on Western blots to prove the production of adequate
amounts of pUL97 and/or pUL44 after transfection (Fig. 4b,
c, and e). This finding was further illustrated by the com-
parison of in vitro kinase assays containing active versus
inactive pUL97 (Fig. 4d, left). pUL44 was strongly phos-
phorylated only in the presence of wild-type pUL97, but
was poorly phosphorylated (close to background level,
compare lane 2 of d with lane 1 of a) by using the catalyt-
ically inactive point mutant pUL97(K355M). In a similar
fashion, the extent of pUL44 phosphorylation was largely
reduced by an incubation with the pUL97-directed inhibitor
NGIC-I (Fig. 4d, right). Thus, pUL44 expressed upon trans-
fection is a specific substrate of the coexpressed pUL97
kinase. Phosphorylation is clearly dependent on the activity
of pUL97 protein kinase, but cellular kinases may also
contribute to full phosphorylation of pUL44 in vivo.
The specificity of phosphorylation reactions was moni-
tored by the use of control samples (Fig. 4f). When histone
2B, known as an in vitro substrate of pUL97 (Marschall et
al., 2001; Baek et al., 2002b), was added to the precipitated
pUL97 kinase, it was clearly phosphorylated. However, the
addition of immunoprecipitated FLAG-tagged HCMV pro-
teins other than pUL44, such as pUL84, IE2p86 (amino
acids 135–579), or pUL26, did not result in phosphoryla-
tion. It should be noted that for IE2p86 and pUL84, the
phosphorylation in HCMV-infected cells is known or pos-
tulated (Harel and Alwine, 1998; Xu et al., 2002; reviewed
by Mocarski and Courcelle, 2001).
In a next step, it should be demonstrated that this phos-
phorylation event is likewise detectable expressed proteins
from infected cells (Fig. 4g–i). HFFs were infected with two
strains of HCMV (laboratory reference strain AD169 and
the endotheliotropic strain TB40E); lysates were prepared
after 3 days and used for the precipitation of pUL97 under
coimmunoprecipitation conditions. The putative protein
complexes were directly assayed in the in vitro kinase assay.
As an essential result, the characteristic autophosphoryla-
tion signal of pUL97 was strongly detectable in the samples
derived from AD169 as well as TB40E infection, but not
from mock infection (Fig. 4g). Furthermore, an additional
phosphorylated band became visible and thus strongly ar-
gued for the successful coimmunoprecipitation of a phos-
phorylation substrate (which was absent from the control
panel showing the non-specific precipitation with preim-
mune serum). The coimmunoprecipitates were further ana-
lyzed on Western blots (Fig. 4h–i). Hereby, the staining was
positive, both for pUL97- as well as pUL44-specific MAbs,
indicating the pUL97–pUL44 coimmunoprecipitation. For
pUL44, at least three bands were detectable under these
conditions, whereby the largest band most likely corre-
sponds to the phosphoprotein identified in Fig. 4g. The
Western blot pattern of UL44 products relates to findings in
other infection experiments, where a single pUL44-specific
polypeptide of 55 kDa was characteristic for the early phase
of infection, but more bands were detected at later time
points. Thus, we confirmed that pUL44 is coprecipitated
with pUL97 from lysates of HCMV-infected fibroblasts.
Furthermore, the phosphorylation data derived from these
coimmunoprecipitates are consistent with the hypothesis
that pUL44 is phosphorylated by pUL97 in vivo.
Discussion
In this study, we provide four lines of evidence illustrat-
ing the interaction between pUL97 and pUL44 of HCMV:
(i) a physical interaction of the two viral proteins was
demonstrated by the yeast two-hybrid system and coimmu-
noprecipitation analyses using infected or transfected cells;
(ii) the pUL97 region (amino acids 366 to 459), responsible
for interaction with pUL44, was mapped by C-terminal and
N-terminal deletion mutagenesis; (iii) a distinct colocaliza-
tion was identified in nuclear replication compartments of
infected fibroblasts; and finally (iv), the phosphorylation of
pUL44 by the pUL97 protein kinase was shown with co-
immunoprecipitated proteins in the in vitro kinase assay.
This indicates that pUL97 associates with pUL44 in the
viral replication complex, phosphorylates this essential fac-
tor, and thus might possess a coregulatory role in viral
genome replication.
The specific role of pUL97 in the viral replication cycle
has only partly been elucidated so far. Generally, the protein
kinase activity of pUL97 seems to be required for a high
efficiency of viral replication (Prichard et al., 1999; Michel
et al., 1996). A publication by Wolf et al. (2001) showed
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Fig. 4. Phosphorylation of pUL44 by pUL97 after coimmunoprecipitation from transfected or infected cells. (a–f) 293 cells were transfected with plasmids for the
expression of pUL44, pUL97, or both (pcDNA-UL44-FLAG, pcDNA-UL97-FLAG, pcDNA-UL97(K355M)-FLAG, or pcDNA3.1 for mock control). Two days
posttransfection, cells were harvested, used for the preparation of cell lysates, and subjected to immunoprecipition with MAb-FLAG. Precipitates were incubated in
the UL97 in vitro kinase assay (IVKA) and phosphorylation products were visualized after SDS–PAGE separation and exposure to autoradiography (a).
Autophosphorylation of pUL97 and phosphorylation of pUL44 is indicated by arrowheads. Note the faint phosphorylation band of pUL44 in the first lane and the
strongly increased phosphorylation of pUL44 in the presence of pUL97 in the second lane. The high level of expression in transfected cells was verified by analysis
of small aliquots of the lysates prior to immunoprecipitation on Western blots using HCMV-specific antibodies, i.e., anti-UL97 (b) or MAb-UL44 (c), respectively.
(d) Phosphorylation of pUL44 derived from coimmunoprecipitation with pUL97 wild-type was compared to that derived from mutant pUL97(K355M) (left) or that
under treatment with the pUL97 inhibitor NGIC-I (100 nM; right). (e) Expression was controlled on Western blots as decribed above (MAb-UL44). (f) As a
specificity control panel, several proteins were subjected to the UL97 in vitro kinase analysis. Histone 2B (H2B) was added directly to the kinase reaction in the form
of a purified protein, while HCMV proteins pUL84, IE2p86, and pUL26 were coexpressed as FLAG-tagged versions in transfected cells as described above,
precipitated, and assayed in the presence of pUL97. (g–i) HFFs were infected with HCMV strains AD169 or TB40E at an m.o.i. of 0.5 or remained mock-infected.
Cell lysates were prepared at 3 days postinfection. Lysates were used for immunoprecipitation with a rabbit antiserum reactive for pUL97 (anti-UL97) or nonreactive
for pUL97 (preimmune serum as a negative control) under the conditions described for coimmunoprecipitation. Putative complexes were subjected to the pUL97
in vitro kinase assay and radioactive phosphorylation products were detected by SDS–PAGE separation and exposure to autoradiography (g). The proteins labeled
in the pUL97 in vitro kinase assay were further characterized by Western blot analysis using HCMV-specific antibodies, i.e., MAb-UL44 (h) or MAb-UL97 (i),
respectively. Note that for pUL44, at least three specific bands are detectable in 3-day infected fibroblasts, while only the upper band appears as phosphorylated form
in the IVKA panel.
that pUL97 acts both at early and at late steps of viral
replication. During the early phase, pUL97 is responsible
for the efficiency of viral DNA synthesis, as illustrated by
the analysis of a UL97-deleted virus mutant. The mutant
was characterized by reduced viral DNA synthesis and
accumulation, showing absence of a well-synchronized
DNA cleavage activity. Furthermore, an important part of
the functional role of pUL97 is also developed during the
late phase of infection and might be directed to viral capsid
assembly. Viral capsid maturation, particularly the phase of
nuclear egress of capsids, was very inefficient in the case of
infection with the UL97-deleted virus mutant, finally lead-
ing to an intranuclear capsid accumulation (Krosky et al.,
2003; Wolf et al., 2001). The intracellular localization of
pUL97 is mostly nuclear with some cytoplasmic signals
becoming visible with increasing time of infection (Michel
et al., 1996). Although the nuclear localization signal of
pUL97 was mapped (Michel et al., 1998) and, in addition to
that, signs of perinuclear accumulation of pUL97 were re-
ported (Marschall et al., 27th International Herpesvirus
Workshop, Cairns, Australia, 2002; Michel et al., 1996), to
our knowledge this is the first study clearly demonstrating
the compartmentalization of this protein in viral nuclear
replication centers. Despite the fact that we demonstrated a
direct interaction of pUL97 with pUL44, it cannot be ruled
out entirely that additional viral or cellular proteins play a
role for this distinct subcellular localization pattern. How-
ever, the finding that pUL97 phosphorylates pUL44, a
prominent component of the replication complex, tempts to
postulate an involvement of pUL97 in the early process of
viral DNA synthesis. Particularly, the pUL97-specific co-
immunoprecipitation of functional complexes from HCMV-
infected fibroblasts, containing the activity to phosphorylate
coprecipitated pUL44, substantiates this concept. Thus, as
concluded from this study and from several previous re-
ports, the functional aspects of pUL97 are complex. They
can in part be explained by the association of pUL97 with
the viral replication machinery, possibly possessing an im-
pact on viral DNA synthesis and, in other parts, by the
involvement of pUL97 in processes which occur later dur-
ing infection.
As far as the definition of natural substrates of pUL97 is
concerned, little clear evidence for the phosphorylation
events during HCMV infection has been provided, but the
phosphorylation in vitro was described for a small number
of proteins. The phosphorylation of histones was reported
by several investigators (He et al., 1997; Marschall et al.,
2001, 2002; Baek et al., 2002b; reviewed by Shugar, 1999).
In a recent study by Baek et al. (2002b), the importance of
specific amino acids (arginine or lysine), five positions
downstream from one of the phosphorylated target residues
(serine) for the efficiency of histone 2B phosphorylation,
was described in detail. In this context, it was speculated
that HCMV might regulate gene expression through the
mechanism of histone phosphorylation and chromatin con-
densation, but this possibility awaits further experimental
evidence.
Another important feature is the autophosphorylation of
pUL97. Autophosphorylation was observed with pUL97
expressed from recombinant baculovirus (He et al., 1997),
vaccinia virus (Michel et al., 1996), plasmid vectors (Mar-
schall et al., 2001), as well as with pUL97 isolated from
virions and infected cells (Wolf et al., 1998; van Zeijl et al.,
1997). Since natural virus mutants, lacking pUL97 auto-
phosphorylation activity, have not been described and point
mutants in UL97 (e.g., ganciclovir resistance mutants)
sometimes possess reduced, but in all cases detectable,
levels of pUL97 autophosphorylation, it is suggestive that
this activity is important for efficient viral replication. It was
postulated that pUL97 autophosphorylation is a prerequisite
of ganciclovir phosphorylation, based on the analysis of a
series of cloned autophosphorylation-negative and -positive
mutants of pUL97 (Michel et al., 1999). Our data confirm
and extend this statement into the activity of protein phos-
phorylation, since we found that deletions within pUL97
abrogating autophosphorylation led to a complete loss of
histone 2B phosphorylation (M. Marschall, unpublished
data). In a very recent publication by Baek et al. (2002a),
however, specific deletion mutants were described, e.g.,
pUL97 N239, which retained a high degree of histone 2B
phosphorylation, despite a largely reduced autophosphory-
lation activity. This might indicate that a wild-type level of
autophosphorylation is not required for the phosphorylation
of exogenous substrates. Alternatively, autophosphorylation
could be involved in protein–protein interactions. Interest-
ingly, in our studies neither the C-terminal deletion mutants
pUL97 (1–595), pUL97 (1–523), and pUL97 (1–459), which
all lack autophosphorylation activity (data not shown), nor the
catalytically inactive mutant pUL97(K355M), are impaired
in the interaction with pUL44 (see yeast two-hybrid data,
Fig. 1a and b). Thus, it will be interesting to see whether
further activities of pUL97, such as pUL44 phosphoryla-
tion, are dependent on autophosphorylation.
There are several similarities between the function of
pUL97 and homologous proteins encoded by other herpes-
viruses. UL97 homologs were identified in all eight human
herpesviruses and the encoded proteins belong to a group of
PKC-related serine/threonine-specific protein kinases (Chee
et al., 1989; Smith and Smith, 1989; Purves and Roizman,
1992; Ng and Grose, 1992; Littler et al., 1992; Michel et al.,
1996; Ansari and Emery, 1999; Park et al., 2000). Some of
these kinases are also capable of phosphorylating nucleo-
sidic substrates, such as GCV, in addition to their natural
protein substrates. This has been proven first for HCMV
pUL97 (Littler et al., 1992; Sullivan et al., 1992), a finding
that explained the virus’ GCV sensitivity in the absence of
a virus-encoded thymidine kinase. Other human herpesvi-
ruses, such as Epstein-Barr virus (EBV), also show GCV
sensitivity during lytic replication, but although a virus-
encoded thymidine kinase exists, GCV phosphorylation
seems to be mediated (in a way similar to HCMV) primarily
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by the viral protein kinase, BGLF4 (Gustafson et al., 1998;
Marschall et al., 2002). BGLF4 performs autophosphoryla-
tion (similar to pUL97) and phosphorylates at least one
further viral target protein, the DNA polymerase processiv-
ity factor BMRF1 (Chen et al., 2000). BMRF1 is homolo-
gous to HCMV pUL44 and exists in multiple phosphory-
lated forms. It was postulated that massive phosphorylation
of BMRF1 might be associated with enhanced protein sta-
bility (Zacny et al., 1999). It should be mentioned that the
phosphorylation of BMRF1, similar to our findings for
pUL44, is mediated mainly but not exclusively by the virus-
encoded protein kinase. Phosphorylation by cellular protein
kinases may play an additional role (Zacny et al., 1999). The
investigation of compounds inhibiting the phosphorylation
of BMRF1, such as the L-riboside benzimidazole 1263W94,
confirmed the idea on the combined action of viral and
cellular kinases: treatment with 1263W94 suppressed the
hyperphosphorylation of BMRF1 in lytically induced EBV-
positive cells. Surprisingly, however, inhibition occurred at
a level other than the direct block of the BGLF4 protein
kinase activity. Thus, the involvement of a cellular kinase
seems suggestive. Moreover, the findings for 1263W94 are
distict from our results for the indolocarbazole NGIC-I: this
strong inhibitor of HCMV replication possesses high spec-
ificity for the virus-encoded protein kinase pUL97, lacking
activity against other kinases (such as BGLF4; Marschall et
al., 2002). Concludingly, NGIC-I may block essential steps
in the pUL97 substrate phosphorylation (e.g., pUL44 phos-
phorylation), which most probably represents the mecha-
nism of virus inhibition.
Our findings provide evidence that pUL97 physically
interacts, phosphorylates, and colocalizes with pUL44 in
viral replication compartments. Since it is known that
pUL44 acts as a processivity factor stimulating the activity
of the HCMV DNA polymerase pUL54, we assume that
phosphorylation of pUL44 might contribute to the regula-
tion of DNA synthesis. Thus, pUL97 is involved in essential
early functions of viral genome replication and represents a
target whose activities are accessible for the specific inter-
ference by antiviralagents.
Materials and methods
Cell culture
Primary human foreskin fibroblasts (HFFs), 293, and
293T cells were cultivated in minimal essential medium
(MEM) or Dulbecco’s MEM, respectively, containing 5%
fetal bovine serum and 100 g/ml gentamicin. HCMVs
AD169 (laboratory strain) and TB40E (endotheliotropic
strain) were propagated in HFFs and used for infection
experiments under standard conditions. Transfection of 293
and 293T cells was performed by the Lipofectamin Plus
method (Invitrogen) in 10-cm dishes at a cell confluency of
75%.
Construction of expression plasmids
Expression constructs were generated with vectors
pcDNA3.1 (Invitrogen), pGBT9, pGAD424 (Clontech),
pACT, and pAS1 (Durfee et al., 1993). pcDNA-UL97-
FLAG, pcDNA-UL97-HA, and pcDNA-UL97(K355M)-
FLAG had been described elsewhere (Marschall et al.,
2001). Note that the mutant pUL97(K355M) is catalytically
inactive due to an amino acid exchange at the invariant
lysine 355 of the ATP binding site. pAS-UL97, pACT-
UL97, and pAS-UL97(K355M) were constructed in a sim-
ilar way by the insertion of the respective UL97 sequence
into vectors pAS1 and pACT. Ten deletion mutants of UL97
were generated by the production of PCR amplificates from
template pcDNA-UL97 using the primers listed below and
subsequent insertion into vector pGBT9. PCR was per-
formed using Vent DNA polymerase (New England Bio-
Labs) in 35 cycles, each composed of 40 s at 95°C for
denaturation, 40 s at 50°C for annealing, and 120 s at 72°C
for polymerization. Likewise, ORF-UL44 was amplified
using genomic DNA of HCMV strain AD169 as a template
and cloned into vector pACT to construct pACT-UL44. For
generating pcDNA-UL44-FLAG, ORF-UL44 was cloned in
fusion to the C-terminal FLAG sequence of the modified
vector pcDNA3.1-FLAG (GACTACAAAGACGATGAC-
GACAAG). For pcDNA-UL84-FLAG, pcDNA-UL26-
FLAG, and pcDNA-IE2p86(135–579)-FLAG, full-length
ORFs (or partial sequences spanning the amino acids indi-
cated) were cloned in fusion to the N-terminal FLAG se-
quence. pCmn-GFP is a green fluorescent protein (GFP)
encoding construct of the vector pCMV/myc/nuc (Invitro-
gen) used as a standard transfection control for human cells.
As a control for yeast two-hybrid experiments, a series of
constructs was used which allowed for the expression of the
HCMV ORFs UL57, UL84, UL122 [IE2p86(135–579);
Hofmann et al., 2000], UL69 (Winkler et al., 2000), UL83
(pp65), UL32 (pp150), and UL26 (Stamminger et al., 2002)
in fusion to either GAL4AD or GAL4-BD of the vectors
listed above. A yeast expression construct for Epstein–Barr
virus-encoded BKRF1 [EBNA1(330–641)] was kindly pro-
vided by Dr. N. Fischer (Fischer et al., 1997). Two com-
mercially available expression constructs (Clontech) were
used as a positive control for the protein interaction in yeast,
pTD1 (SV40-T) and pVA3 (p53).
Oligonucleotides
Synthetic oligonucleotide primers for PCR were pur-
chased from Sigma. UL97-specific sequences are under-
lined. Restriction sites are bold-printed and the FLAG se-
quence is indicated by italics:
5-UL97-1-EcoRI:
(TAGT GAA TTC ATG TCC TCC GCA CTT CGG
TCT CGG)
5-UL97-49-EcoRI:
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(TAGT GAA TTC ATG GCG GTG CAG GCC GCG
CAG GCC)
5-UL97-111-EcoRI:
(TAGT GAA TTC ATG CGT GAC GGA GAA
AAA GAG GAC GCG GCT)
5-UL97-181-EcoRI:
(TAGT GAA TTC ATG GAC CCC TCG GAC AGC
GTG AGC GGC)
5-UL97-366-EcoRI:
(TAGT GAA TTC ATG ACG GTC TGG ATG TCG
GGC CTG ATC CGC ACG)
3-UL97-110-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC CAC GTC ACT TCG AAC GCA
TGC G)
3-UL97-180-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC GCT GCC GCC GGT GAA GAG
AGC)
3-UL97-365-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC GAG CAC CGT CTC GCT GTG
CTT ACG C)
3-UL97-459-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC GGG TGT AAT GTC AAA GTG
GCA TAC ACG)
3-UL97-523-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC GAA AGC AGG GTG GTA ACA
TTC GCG)
3-UL97-595-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC CAA CGC GCG GCA GGC CGC
GC)
3-UL97-707-SaII-FLAG:
(CCG GTC GAC TTA CTT GTC GTC ATC GTC
TTT GTA GTC CTC GGG GAA CAG TTG GCG
GCA)
Yeast two-hybrid analysis
Protein interactions were analyzed by the use of GAL4
fusion proteins in a standard yeast two-hybrid protocol
(Fields and Song, 1989) including minor modifications.
Saccharomyces cerevisiae strain Y153 was transformed by
the lithium acetate method (Gietz et al., 1992) using plasmid
pAS-UL97 to express pUL97-GAL4BD as a bait. As puta-
tive interactors, pUL44 and several control proteins were
expressed as GAL4AD fusion proteins. Expression was
confirmed by Western blotting using the monoclonal anti-
bodies MAb-GAL4BD and MAb-GAL4AD (Clontech, Hei-
delberg). The presence of both or either of the two plasmids
was stably maintained by growth selection for combined
tryptophan/leucine prototrophy or a single prototrophy, re-
spectively. Primary transformants were further selected for
growth on histidine-deficient plates (indicating protein in-
teraction) containing 30 mM 3-aminotriazole. His-compe-
tent clones were analyzed for -Gal activity by filter lift
tests. The interaction was then quantified by o-nitrophenyl
galactopyranoside (ONPG) assays as described elsewhere
(Guarente, 1983).
Coimmunoprecipitation analysis
HFFs were infected with HCMV strain AD169 at m.o.i.s
of 1, 0.1, and 0 as an uninfected control (approximately 5 
106 cells per coimmunoprecipitation sample). Three days
postinfection, cells were harvested by trypsinization, lysed
in 1 ml of CoIP buffer (50 mM Tris–HCl pH 8.0, 150 nM
NaCl, 5 mM EDTA, 0.5% NP-40, 1 mM PMSF, 2 g/ml
aprotinin, 2 g/ml leupeptin, and 2 g/ml pepstatin) and
used for immunoprecipitation. For this, 4 l of a monoclo-
nal antibody, e.g., MAb-UL44 (supplied by B. Plachter,
Univ. Mainz, Germany), or a non-UL44-reactive MAb as a
control was incubated for 4 h at 4°C under rotation, before
protein A–sepharose beads (Amersham, Pharmacia Biotech;
2.5 mg in a 50-l volume of CoIP buffer) were added for
complexation. The complexes were pelleted in an Eppen-
dorf centrifuge (5000 rpm, 2 min), washed four times with
ColP buffer, and denturated in 50 l of boiling mix buffer.
Samples were heat-denatured for 10 min at 95°C and used
for separation on 12.5% SDS–PAGE. Thereafter, gels were
subjected to a standard Western blotting procedure and
analyzed by the use of MAb-UL97 (supplied by D. Michel,
Univ. Ulm, Germany) for the coimmunoprecipitation of
pUL97. Staining was performed by the enhanced chemilu-
minescence (ECL) method according to manufacturer’s pro-
tocol (New England Biolabs). Alternatively, for the coim-
munoprecipitation of two tagged viral proteins (FLAG- or
HA-tagged, respectively) in the absence of HCMV replica-
tion, 293T cells were transfected with two expression con-
structs and lysed 2 days posttransfection, and lysates were
subjected to the procedure described above using of 2 l
MAb-HA (HA.11; BAbCO, Richmond, CA, USA).
Indirect immunofluorescence test
HFFs were grown on coverslips in six-well plates and
infected with HCMV strain AD169 at an m.o.i. of 0.1. Four
days postinfection, cells were washed twice with PBS and
used for fixation with ice-cold methanol for 10 min. Cov-
erslips were moved to fresh six-well plates and blocking
was achieved by preincubation with nonspecific horse se-
rum for 30 min at 37°C. Two primary antibodies, e.g., rabbit
anti-UL97 (supplied by D. Michel, Univ. Ulm, Germany)
and mouse MAb-UL44, were used for the combined incu-
bation for 90 min at 37°C. Secondary antibodies were cho-
sen for double-staining in green (anti-rabbit-FITC, Di-
anova) and red (anti-mouse-Cy3, Dianova), respectively,
and incubated for 45 min at 37°C. Washing steps were
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performed by three incubation steps in PBS each for 10 min.
Nuclear counterstaining was carried out using Vectashield
mounting medium with DAPI (Vector Laboratories, Burlin-
game, CA).
Data for immunofluorescence were collected by the use
of a Zeiss Axiovert-135 microscope at magnifications of 
400 and  630. FITC and Cy3 were analyzed at at excita-
tion wavelengths of 450–490 and 510–560 nm, respec-
tively, using filter sets 10 and 14 (Zeiss, Jena, Germany).
Images were recorded with a Cooled Spot Color Digital
Camera (Diagnostic Instruments, Burroughs, MI) and pro-
cessed by using the Metaview imaging series in combina-
tion with Adobe Photoshop and Microsoft CorelDRAW
software. For double staining, the two channels were over-
laid by the computer for dual images (Merge). Each exper-
iment was repeated at least three times.
In vitro kinase assay (IVKA)
The kinase activity of pUL97 was determined in vitro
after recombinant expression in transfected 293 cells as a
FLAG-tagged protein and immunoprecipitation from cell
lysates (MAb-FLAG M2, Sigma) as described recently
(Marschall et al., 2001). pUL44 was coexpressed in 293
cells and coimmunoprecipitated from the cell lysates to
expose it directly to the in vitro kinase assays as a putative
substrate of pUL97. The inhibitor of pUL97 kinase activity,
indolocarbazole compound NGIC-I, was added to the ki-
nase reaction (100 nM). Alternatively, for the coimmuno-
precipitation of native viral proteins expressed during
HCMV replication, HFFs were infected with strains AD169
and TB40E at an m.o.i. of 0.5 and lysed 3 days posttrans-
fection (approximately 2.5  107 cells per IVKA reaction)
and lysates were subjected to the procedure described above
using of 2 l of rabbit anti-UL97 antiserum (PepAs 1343;
Marschall et al., 2002).
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